biophy

Leveraging the possibilities of modern science and advanced technologies, BioPhy is committed to transforming the way promising drugs are identified, developed, and tested. With the help of our patent-pending predictive AI engine BioLogic, and our generative AI solution BioPhyRx, we work to enhance the outcomes of clinical trials, reduce failure and non-compliance rates, accelerate the pace of developing new drugs, and moreover, improve the quality of healthcare outcomes across the globe. Meet the founders: Dave Latshaw II, Ph.D.: https://www.linkedin.com/in/davidlatshawii/ Steve Truong: https://www.linkedin.com/in/stevenhtruong1 Daniel Sciubba, MD: https://www.linkedin.com/in/daniel-sciubba-md-wharton-mba-cand BioPhy is a Philadelphia-based, venture backed company. Contact us at [email protected]

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.

Hargrove Life Sciences

Hargrove Life Sciences, a division of the full-service EPC firm Hargrove, is based in Philadelphia and serves pharmaceutical, biotechnology, food/beverage, and specialty chemical clients in the US and abroad. In an industry where the facility and “clean” process elements must work together, our experienced Teammates understand how to design and build in order to meet the rigorous GMP standards. Our teams of engineers, architects, and project managers offer extensive experience in the planning of greenfield facilities as well as the renovation and expansion of existing process development, clinical manufacturing, and commercial operations. In addition, Hargrove has a culture and system of seamless cross-office collaboration. Our clients benefit from all the expertise of a specialized engineering firm supported by the experience and capabilities of a larger firm with a broader focus. Contact us at info@hargrove-epc or 877-388-8356.

Spark Therapeutics, Inc.

At Spark® Therapeutics, we believe in a world where no life is limited by disease.   We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. Our mission is to unlock the power of gene therapy to accelerate healthcare transformation.     Since our founding, we have been committed to bringing a wide range of expertise to build a fully integrated gene therapy company focused on inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. We are seeking talented individuals with diverse experiences, abilities and interests who have the curiosity, courage and drive to reimagine a new health care paradigm.     Join us on a journey through uncharted territory – seeking to bring gene therapy to people worldwide. The resilience of the people we serve is our inspiration to break barriers, as we strive to turn genes into medicine. Spark is a member of the Roche Group.     Know that working at Spark® Therapeutics is not just another job; it is a once-in-a-lifetime opportunity. We embrace the challenges before us and the uncertainty inherent in them. Ultimately, we are working to create a world where no life is limited by disease. To learn more about Spark and our open positions, visit www.sparktx.com. You can also find us on Twitter at @Spark_tx.  Spark’s social media sites are monitored from Monday to Friday during normal business hours. Questions or concerns should be directed here: https://sparktx.com/contact-us/.

Clario

Clario is a leading healthcare research and technology company that generates high quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Since our founding more than 50 years ago, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported clinical trials over 26,000 times in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2019. For more information, visit Clario.com